We navigate the tricky pharma regulatory environment with clear and concise advice. We help with compliance on regulatory and policy issues, ethics, data exclusivity and protection, labelling and legal metrology. We also work on niche intellectual property matters as well as general commercial and operational litigations faced by pharmaceutical companies. We develop efficient operating structures to optimise tax costs in the supply chain.
We work with clients along most parts of the product lifecycle, including clinical trials; product approvals; patent filings; manufacturing, distribution, licensing agreements; pricing issues; branding and promotion; product recall; data protection and disputes. Our team has extensive expertise and experience on commercial arrangements and transactions in the pharmaceuticals sector including M&A, collaborations and fund raising.
Our cross-practice group comprises experts from different domains relevant to this sector. The team has diverse skills and experience to support needs of stakeholders across the industry value chain. Our lawyers have deep insights on key industry trends and risks. We advise local and multinational clients in several critical and strategic areas. As a full-service law firm, we are able to help clients navigate through the complex regulatory environment and offer robust legal and commercial solutions aligned with business objectives.
Advised on acquisition of stake in Fortis Healthcare Limited and Fortis Malar Hospitals Limited for a total consideration of USD 1.1 billion
Advised clients in relation to acquisition of Kraft Heinz’s consumer brand business jointly with Cadila for a total consideration of USD 630 million
Acquisition of 74% stake in Gland Pharma Limited for total consideration of USD 1.09 billion approximately.
Acquisition of the domestic formulations business of Unichem Laboratories Ltd through a business transfer agreement for a total consideration of USD 556 million
Advised on sale of some of its branded domestic formulations business in India and Nepal, to Torrent Pharmaceuticals Limited by way of a slump sale for a total consideration of USD 324 million
Advised on major three-part global transaction with Novartis AG, pursuant to which GSK formed a consumer health joint venture with Novartis for a total consideration of USD 20 billion
Advised on regulatory aspects in relation to sale of its contraceptive business to Mylan Inc for a total consideration of USD 800 million
Advised on acquisition of the injectable pharmaceutical business of Orchid Chemicals and Pharmaceuticals Ltd for a total consideration of USD 400 million
Advised on transfer of Claris Lifesciences Limited’s infusions business to Claris Otsuka Limited, and thereafter, Otsuka Pharmaceutical Co., Ltd and Mitsui & Co’s investment in Claris Otsuka Limited for a total consideration of USD 170 million
“Khaitan will deal with matters promptly and efficiently. They will always seek to give our clients sound commercial advice” another client adds.”
